What's Happening?
The Schall Law Firm is urging investors of ImmunityBio, Inc. to join a class action lawsuit alleging securities fraud. The lawsuit claims that ImmunityBio made false and misleading statements about its Anktiva drug, resulting in investor losses. The class period
spans from January 19, 2026, to March 24, 2026. Investors are invited to contact the firm to discuss their rights and potentially recover losses. The class has not yet been certified, and investors must act before May 26, 2026.
Why It's Important?
This lawsuit could impact ImmunityBio's reputation and financial standing. If the company is found liable for securities fraud, it may face significant legal and financial consequences. Investors have the opportunity to recover losses, emphasizing the importance of accountability and transparency in corporate communications. The case underscores the need for companies to provide accurate information to maintain investor confidence and market integrity.
